Cargando…
Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma
BACKGROUND: In patients with breast cancer, HER2 gene expression is of a great importance in reacting to Herceptin treatment. To evaluate this event, immunohistochemistry (IHC) has been done routinely on the basis of scoring it and so the patients were divided into 4 groups. Lately, as there have be...
Autores principales: | Atabati, Hadi, Raoofi, Amir, Amini, Abdollah, Farahani, Reza Masteri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Republic of Macedonia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290434/ https://www.ncbi.nlm.nih.gov/pubmed/30559846 http://dx.doi.org/10.3889/oamjms.2018.455 |
Ejemplares similares
-
Monosomy 3 by chromogenic in situ hybridization (CISH) in Iranian patients with uveal melanoma
por: Naseripour, Masood, et al.
Publicado: (2015) -
Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
por: Ali, Ali Hussein Mohammed, et al.
Publicado: (2019) -
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
por: Arnould, L, et al.
Publicado: (2003) -
Predicting Effects of Clinicopathological Variables on Her2 Gene Amplification by Chromogenic in situ Hybridization (CISH) in IHC Her2 (2+) Breast Cancer Patients; A Study from Iran
por: Hashemi Bahremani, Mohammad, et al.
Publicado: (2020) -
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
por: Madrid, Manuelito A, et al.
Publicado: (2004)